The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Extramedullary disease in multiple myeloma: a systematic literature review
Open accessAbstract
Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. Several different definitions of EMD have been used in the published literature. We advocate that true EMD is restricted to soft-tissue plasmacytomas that arise due to hematogenous spread and have no contact with bony structures. Typical sites of EMD vary according to the phase of MM. At diagnosis, EMD is typically found in skin and soft tissues; at relapse, typical sites involved include liver, kidneys, lymph nodes, central nervous system (CNS), breast, pleura, and pericardium. The reported incidence of EMD varies considerably, and differences in diagnostic approach between studies are likely to contribute to this variability. In patients with newly diagnosed MM, the reported incidence ranges from 0.5% to 4.8%, while in relapsed/refractory MM the reported incidence is 3.4 to 14%. Available data demonstrate that the prognosis is poor, and considerably worse than for MM without soft-tissue plasmacytomas. Among patients with plasmacytomas, those with EMD have poorer outcomes than those with paraskeletal involvement. CNS involvement is rare, but prognosis is even more dismal than for EMD in other locations, particularly if there is leptomeningeal involvement. Available data on treatment outcomes for EMD are derived almost entirely from retrospective studies. Some agents and combinations have shown a degree of efficacy but, as would be expected, this is less than in MM patients with no extramedullary involvement. The paucity of prospective studies makes it difficult to justify strong recommendations for any treatment approach. Prospective data from patients with clearly defined EMD are important for the optimal evaluation of treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 1×
“Published trials of other CAR-T therapies have reported responses in patients with soft-tissue plasmacytomas, but do not report data specifically for patients with EMD [44, 45].”
BackgroundSelf-citationAnti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Cavo, M., Terpos, E., Nanni, C., Moreau, P., Lentzsch, S., Zweegman, S., Hillengaß, J., Engelhardt, M. M., Usmani, S. Z., Vesole, D. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30189-4 · Cited by 547
Self-citationVarettoni, M., Corso, A., Pica, G.-M., Mangiacavalli, S., Pascutto, C., & Lazzarino, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp329 · Cited by 489
Usmani, S. Z., Heuck, C. J., Mitchell, A., Szymonifka, J. D., Nair, B. P., Hoering, A., Alsayed, Y. M., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 395
Self-citationBladé, J., de Larrea, C. F., Rosiñol, L., Cibeira, M. T., Jiménez, R., & Powles, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9290 · Cited by 388
Self-citationde Larrea, C. F., Kyle, R. A., Durie, B. G. M., Ludwig, H., Usmani, S. Z., Vesole, D. H., Hájek, R., Miguel, J. F. S., Sezer, O., Sonneveld, P., et al. (2012) · Leukemia · doi:10.1038/leu.2012.336 · Cited by 384
Self-citationCaers, J., Paiva, B., Zamagni, E., Leleu, X. P., Bladé, J., Kristinsson, S. Y., Touzeau, C., Abildgaard, N., Terpos, E., Heusschen, R., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0549-1 · Cited by 338
Self-citationMoreau, P., Attal, M., Caillot, D., Macro, M., Karlin, L., Garderet, L., Facon, T. T. F., Benboubker, L., Escoffre‐Barbe, M., Stoppa, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2975 · Cited by 334
Self-citationExtramedullary multiple myeloma
Bhutani, M., Foureau, D., Atrash, S., Voorhees, P. M., & Usmani, S. Z. (2019) · Leukemia · doi:10.1038/s41375-019-0660-0 · Cited by 242
Self-citationShort, K. D., Rajkumar, S. V., Larson, D. R., Buadi, F. K., Hayman, S. R., Dispenzieri, A. A., Gertz, M. A., Kumar, S. K., Mikhael, J. R., Roy, V., et al. (2011) · Leukemia · doi:10.1038/leu.2011.29 · Cited by 209
How I treat extramedullary myeloma
Touzeau, C., & Moreau, P. (2015) · Blood · doi:10.1182/blood-2015-07-635383 · Cited by 190
Self-citationPour, L., Sevcikova, S., Grešlíková, H., Kupská, R., Májková, P., Zahradová, L., Sandecká, V., Adam, Z., Krejčí, M., Kuglík, P., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.094409 · Cited by 186
Rosiñol, L., Beksac, M., Zamagni, E., Van de Donk, N. W. C. J., Anderson, K. C., Badros, A., Caers, J., Cavo, M., Dimopoulos, M., Dispenzieri, A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17338 · Cited by 179
Self-citationZamagni, E., Nanni, C., Dozza, L., Carlier, T., Bailly, C., Tacchetti, P., Versari, A., Chauvie, S., Gallamini, A., Gamberi, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00386 · Cited by 151
Self-citationJurczyszyn, A. J., Grząśko, N., Gozzetti, A., Czepiel, J., Cerase, A., Hungria, V., Crusoé, E. D. Q., Dias, A. L. M. S., Vij, R., Fiala, M. A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24351 · Cited by 146
Self-citationGozzetti, A., Cerase, A., Lotti, F., Rossi, D., Palumbo, A., Petrucci, M. T., Patriarca, F. F., Nozzoli, C., Cavo, M., Offidani, M., et al. (2011) · Cancer · doi:10.1002/cncr.26447 · Cited by 134
Chang, H., Sloan, S. R., Li, D., & Stewart, A. K. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05199.x · Cited by 124
Chen, C. I., Masih‐Khan, E., Jiang, H., Rabea, A. M., Cserti-Gazdewich, C. M., Jimenez-Zepeda, V. H., Chu, C., Kukreti, V., Trudel, S., Tiedemann, R. E., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12414 · Cited by 121
Gagelmann, N., Eikema, D.-J., Iacobelli, S., Köster, L., Nahi, H., Stoppa, A., Masszi, T., Caillot, D., Lenhoff, S., Udvardy, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.178434 · Cited by 114
Extramedullary multiple myeloma
Weinstock, M., & Ghobrial, I. M. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.740562 · Cited by 105
Extramedullary disease in multiple myeloma – controversies and future directions
Ševčı́ková, S., Minařík, J., Štork, M., Jelı́nek, T., Pour, L., & Hájek, R. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.002 · Cited by 104
Cytogenetics of extramedullary manifestations in multiple myeloma
Billecke, L., Penas, E. M. M., May, A. M., Engelhardt, M. M., Nagler, A., Leiba, M., Schiby, G., Kröger, N. M., Zustin, J., Marx, A. H., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12223 · Cited by 100
Rasche, L., Bernard, C., Topp, M. S., Kapp, M., Duell, J., Wesemeier, C., Haralambieva, E., Maeder, U., Einsele, H., & Knop, S. T. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1414-5 · Cited by 99
Self-citationWeinstock, M. A., Aljawai, Y. M., Morgan, E. A., Laubach, J. P., Gannon, M., Roccaro, A. M., Varga, C., Mitsiades, C. S., Paba‐Prada, C. E., Schlossman, R. L., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13383 · Cited by 93
Self-citationBeksaç, M., Seval, G. C., Kanellias, N., Coriu, D., Rosiñol, L., Özet, G., Goranova-Marinova, V. S., Ünal, A., Bila, J., Özsan, H., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219295 · Cited by 93
Self-citationGagelmann, N., Eikema, D.-J., Köster, L., Caillot, D., Pioltelli, P. E., Lleonart, J. B., Reményi, P., Blaise, D., Schaap, N. P., Trněný, M., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.07.004 · Cited by 90
Deng, S., Xu, Y., An, G., Sui, W., Zou, D., Zhao, Y., Qi, J., Li, F., Hao, M., & Qiu, L. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.12.013 · Cited by 70
Montefusco, V., Gay, F., Spada, S., Paoli, L. D., Raimondo, F. D., Ribolla, R., Musolino, C., Patriarca, F. F., Musto, P., Galieni, P., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219139 · Cited by 63
Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma
Abdallah, A.-O. A., Atrash, S., Shahid, Z., Muzaffar, J., Grazziutti, M., Apewokin, S. K., Kumar, N. S., Restrepo, A., Waheed, S., van Rhee, F., et al. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.11.004 · Cited by 62
Self-citationExtramedullary Disease in Multiple Myeloma
Jagosky, M. H., & Usmani, S. Z. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00568-3 · Cited by 62
Self-citationMyelomatous Involvement of the Central Nervous System
Paludo, J., Painuly, U., Kumar, S. K., Gonsalves, W. I., Rajkumar, S. V., Buadi, F. K., Lacy, M. Q., Dispenzieri, A. A., Kyle, R. A., Mauermann, M. L., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.010 · Cited by 60
p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma
Sheth, N., Yeung, J., & Chang, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.010 · Cited by 59
Moreau, P., Zweegman, S., Perrot, A., Hulin, C., Caillot, D., Facon, T. T. F., Leleu, X. P., Belhadj, K., Karlin, L., Benboubker, L., et al. (2019) · Blood · doi:10.1182/blood-2019-123143 · Cited by 59
Self-citationDeng, H., Liu, M., Yuan, T., Zhang, H., Cui, R., Li, J., Yuan, J., Wang, X., Wang, Y., & Deng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720571 · Cited by 57
Katodritou, E., Terpos, E., Kastritis, E., Delimpasis, S., Symeonidis, A. S., Repousis, P., Kyrtsonis, M., Vadikolia, C., Michalis, E., Polychronidou, G., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2484-y · Cited by 54
P53 deletion may drive the clinical evolution and treatment response in multiple myeloma
López‐Anglada, L., Gutierrez, N. C., Garcı́a, J. L., Mateos, M., Flores, T., & Miguel, J. F. S. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01399.x · Cited by 54
Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma
Liu, Y., Jelloul, F. Z., Zhang, Y., Bhavsar, T. M., Ho, C., Rao, M., Lewis, N. E., Cimera, R., Baik, J., Sigler, A. M., et al. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001459 · Cited by 48
Lee, D. T., Kalff, A., Low, M. S. Y., Gangatharan, S. A., Ho, P. W., Bajel, A. R., Ritchie, D., Grigg, A., & Spencer, A. G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12404 · Cited by 47
Katodritou, E., Gastari, V., Verrou, E., Hadjiaggelidou, C., Varthaliti, M., Georgiadou, S., Laschos, K., Xirou, P., Yiannaki, E. E., Constantinou, N., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.036 · Cited by 46
Zhou, X., Flüchter, P., Nickel, K., Meckel, K., Messerschmidt, J., Böckle, D., Knorz, S., Steinhardt, M., Krummenast, F., Danhof, S., et al. (2020) · Cancers · doi:10.3390/cancers12041035 · Cited by 45
Self-citationRasche, L., Strifler, S., Duell, J., Rosenwald, A., Buck, A. K., Maeder, U., Einsele, H., & Knop, S. T. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2023-2 · Cited by 35
Self-citationAvivi, I. M., Cohen, Y. C., Suska, A., Shragai, T., Mikala, G., Garderet, L., Gueye, M. S., Glickman, S., Jayabalan, D. S., Niesvizky, R., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25579 · Cited by 34
Self-citationPapanikolaou, X. D., Repousis, P., Τζένου, Τ., Maltezas, D., Kotsopoulou, M., Megalakaki, K., Angelopoulou, M. K., Dimitrakoloulou, E., Koulieris, E., Bartzis, V., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.746683 · Cited by 33
Batsukh, K., Lee, S., Min, G. J., Park, S. S., Jeon, Y., Yoon, J., Cho, B., Eom, K., Kim, Y., Kim, H., et al. (2017) · Immune Network · doi:10.4110/in.2017.17.4.250 · Cited by 29
Wang, B., Liu, J., Zhao, W., Chen, Y., Cao, X.-M., Yang, Y., Zhang, Y., Wang, F., Zhang, P., Lei, B., et al. (2020) · Blood · doi:10.1182/blood-2020-140243 · Cited by 23
Usmani, S. Z., Berdeja, J. G., Jakubowiak, A. J., Agha, M., Cohen, A., Madduri, D., Hari, P., Yeh, T., Olyslager, Y., Banerjee, A., et al. (2021) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2021.10.460 · Cited by 22
Self-citationÇiftçiler, R., Göker, H., Demiroğlu, H., Aksu, S., Sayınalp, N., Haznedaroğlu, İ. C., Malkan, Ü. Y., Büyükaşık, Y., & Ozcebe, O. I. (2019) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2019.2019.0061 · Cited by 21
Bommer, M., Kull, M., Teleanu, V., Schwarzwälder, P., Feuring‐Buske, M., Kroenke, J., Bunjes, D. W., & Langer, C. (2018) · Acta Haematologica · doi:10.1159/000489484 · Cited by 20
Muchtar, E., Raanani, P., Yeshurun, M., Shpilberg, O., & Magen‐Nativ, H. (2014) · Acta Haematologica · doi:10.1159/000354830 · Cited by 19
Extramedullary Myeloma Spread Triggered by Surgical Procedures: An Emerging Entity?
Rosiñol, L., de Larrea, C. F., & Bladé, J. (2014) · Acta Haematologica · doi:10.1159/000354833 · Cited by 16
Self-citationBeksaç, M., Seval, G. C., Kanellias, N., Coriu, D., Rosiñol, L., Özet, G., Goranova-Marinova, V. S., Unal, A., Bila, J., Özsan, H., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.278272 · Cited by 13
Self-citationRichardson, P. G. G., Mateos, M., Oriol, A., Larocca, A., Cavo, M., Rodríguez‐Otero, P., Leleu, X. P., Norkin, M., Nadeem, O., Hiemenz, J. W., et al. (2020) · Blood · doi:10.1182/blood-2020-137118 · Cited by 11
Self-citationPredictors of inferior clinical outcome in patients with standard‐risk multiple myeloma
Badar, T., Srour, S. A., Bashir, Q., Shah, N. D., Alatrash, G., Hosing, C. M., Popat, U., Nieto, Y. L., Orlowski, R. Z., Champlin, R. E., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12826 · Cited by 8
Cited by
Sorted by citations
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664
Malard, F., Neri, P. E., Bahlis, N. J., Terpos, E., Moukalled, N. M., Hungria, V., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 387
Avet‐Loiseau, H., Davies, F. E., Samur, M., Corre, J., D’Agostino, M., Kaiser, M., Raab, M. S., Weinhold, N., Gutierrez, N. C., Paiva, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01893 · Cited by 211
Self-citationReal-world analysis of teclistamab in 123 RRMM patients from Germany
Riedhammer, C., Bassermann, F. C., Besemer, B., Bewarder, M., Brunner, F., Carpinteiro, A., Einsele, H., Faltin, J., Frenking, J. H., Gezer, D., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02154-5 · Cited by 132
Self-citationMezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
Richardson, P. G. G., Trudel, S., Popat, R., Mateos, M., Vangsted, A. J., Ramasamy, K., Martínez‐López, J., Quach, H., Orlowski, R. Z., Arnao, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303194 · Cited by 102
Self-citation
Metadata
- Authors
- Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., & Richardson, P.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Centre Hospitalier Universitaire de Liège (BE)
- Jagiellonian University (PL)
- Nantes Université (FR)
- Universitätsklinikum Würzburg (DE)
- Levine Cancer Institute (US)
- Istituto di Ematologia di Bologna (IT)
- Harvard University (US)
- Corresponding author
- Bladé, Joan
- ORCID
- Venue
- Blood Cancer Journal
- Published
- 2022-03-21
- Volume
- 12
- Issue
- 3
- Pages
- 45-45
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8938478
- OpenAlex
- W4220896277
- Cited by
- 319
- References
- 56
- Citations by year
- 2026: 79 · 2025: 107 · 2024: 73 · 2023: 44 · 2022: 14
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion, cc-by)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- extramedullary disease, multiple myeloma, soft tissue plasmacytoma, hematogenous spread, relapsed/refractory multiple myeloma, central nervous system involvement, leptomeningeal involvement, prognosis, treatment outcomes
- MeSH terms
- Humans, Multiple Myeloma, Neoplasm Recurrence, Local, Plasmacytoma, Prospective Studies, Retrospective Studies, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
